【火热】新华制药拿下4亿热销品种,成功开拓新市场

米内网
Feb 27

精彩内容近期,山东淄博新达制药的沙格列汀二甲双胍缓释片(I)成功获批,成为了新华制药旗下首款口服复方降糖药,意义重大。沙格列汀二甲双胍是口服复方降糖药TOP5品种,2024年在中国三大终端六大市场的销售额涨至4亿元。今年以来,新华制药已收获了两个重磅新品。图1:新华制药获批的新产品来源:国家药监局官网沙格列汀二甲双胍是由沙格列汀(DPP-4抑制剂)和二甲双胍(双胍类)组成的复方口服降糖药,主要用于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10